909187-64-0

Basic information

• Product Name: 3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)-
• Synonyms: 3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)-;6-benzyl-1,2,4,5,6,7-hexahydropyrazolo[3,4-c]pyridin-3-one;6-Benzyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3(2H)-one;Benzyl-1,2,4,5,6,7-hexahydropyrazolo[3,4-c]pyridin-3-one;1,2,4,5,6,7-Hexahydro-6-(phenylmethyl)-3H-pyrazolo[3,4-c]pyridin-3-one;6-Benzyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3(2H);6-benzyl-2,4,5,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-one
• CAS NO: 909187-64-0
• Molecular Formula: C₁₃H₁₅N₃O
• Molecular Weight: 229.28
• Mol File: 909187-64-0.mol

Chemical Properties

• Appearance: /
• Density: 1.27
• Refractive Index: 1.654
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.89±0.20(Predicted)
• CAS DataBase Reference: 3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)-(909187-64-0)
• EPA Substance Registry System: 3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)-(909187-64-0)

Safety Data

• Hazardous Substances Data: 909187-64-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)is utilized as a key component in the development of new drugs due to its distinctive chemical structure and potential medicinal properties. It serves as a building block for designing novel therapeutic agents that could address various health conditions and diseases.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)is employed as a subject of study to understand its interactions with biological targets. This research is crucial for elucidating its mechanism of action and optimizing its properties to enhance its therapeutic potential.
Used in Drug Development:
3H-PYRAZOLO[3,4-C]PYRIDIN-3-ONE, 1,2,4,5,6,7-HEXAHYDRO-6-(PHENYLMETHYL)is leveraged in the process of drug development to create new pharmaceutical entities. Its unique structure and properties make it a valuable asset in the synthesis of compounds with improved efficacy, selectivity, and safety profiles for treating a range of medical conditions.

InChI:InChI=1/C13H15N3O/c17-13-11-6-7-16(9-12(11)14-15-13)8-10-4-2-1-3-5-10/h1-5H,6-9H2,(H2,14,15,17)

Upstream product

• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 

Relevant articles and documents

Synthesis of 3-(hetero)aryl tetrahydropyrazolo[3,4-c]pyridines by Suzuki-Miyaura cross-coupling methodology

A new synthetic route to 3-(heteroaryl) tetrahydropyrazolo[3,4-c]pyridines has been developed that uses the Suzuki-Miyaura cross-coupling of a triflate 6 with (hetero)aryl boronic acids or esters. Using Pd(OAc)2 and XPhos or an XPhos precatalyst, a diverse range of substituents at the C3 position of the tetrahydropyrazolo[3,4-c]pyridine skeleton were prepared. The use of pivaloyloxymethyl and benzyl protection also offers the potential to differentially functionalize the pyrazole and tetrahydropyridine nitrogens.

PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS

The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Pyrazolo piperidine derivatives as NADPH oxidase inhibitors

The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.